ALGS
Market open

Aligos Therapeutics/ALGS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aligos Therapeutics

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Ticker

ALGS
Trading on

Industry

Biotechnology

Employees

68

ALGS Metrics

BasicAdvanced
$45M
Market cap
-
P/E ratio
-$15.66
EPS
2.18
Beta
-
Dividend rate
$45M
2.18
$30.00
$6.76
110K
4.226
4.012
9.642
14.632
-53.97%
-110.67%
4.388
0.66
0.66
-0.41
-53.82%
-67.32%
48.05%
-48.44%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy ALGS

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aligos Therapeutics stock?

Aligos Therapeutics (ALGS) has a market cap of $45M as of October 15, 2024.

What is the P/E ratio for Aligos Therapeutics stock?

The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of October 15, 2024.

Does Aligos Therapeutics stock pay dividends?

No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of October 15, 2024.

When is the next Aligos Therapeutics dividend payment date?

Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.

What is the beta indicator for Aligos Therapeutics?

Aligos Therapeutics (ALGS) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.